OLV Ziekenhuis Aalst Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2012
NCT01768702
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

OLV Ziekenhuis Aalst (Belgium)

Active Ingredients

Drugs in Phase 3 Trials (1)

bone marrow-derived cardiopoietic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1